ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lantern Pharma Reacquires Irofulven from Allarity Therapeutics
July 29, 2021Allarity Therapeutics A/S and Lantern Pharma Inc. have entered an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full responsibility for future clinical development and commercialization. -
Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP
July 06, 2021Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has provided a positive administrative acceptance and review notification for the Company's PMA application for its Dovitinib-DRP®
Pharma Sources Insight January 2025
